Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 18565862.
- Also identified by DOI 10.1056/NEJMoa0800251 and PMC identifier 3277288.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We developed an in vitro method for isolating and expanding autologous CD4+ T-cell clones with specificity for the melanoma-associated antigen NY-ESO-1. We infused these cells into a patient with refractory metastatic melanoma who had not undergone any previous conditioning or cytokine treatment. We show that the transferred CD4+ T cells mediated a durable clinical remission and led to endogenous responses against melanoma antigens other than NY-ESO-1.
Medical subject headings
- Antigens, Neoplasm
- CD4-Positive T-Lymphocytes
- Immunotherapy
- Melanoma
- Membrane Proteins